PhD student position : Patient-derived screening platform for GBM - AG1122

Funded by the European Union and as part of the HORIZON-MSCA Doctoral network, 10 new PhD student positions are available, including 1 at the LIH.  We are seeking candidates of excellence wishing to pursue a PhD degree in the field of cancer precision medicine.
Rue Nicolas-Ernest Barblé 6, Luxembourg L-1210, Luxembourg
15/11/2022 09:40:31

                    The pan-European, academic & private sector GLIORESOLVE Doctoral Network, which comprises 10 funded beneficiaries and 11 associated partner organisations representing 10 countries, seeks to train 10 innovative, creative and entrepreneurial PhD students over 3 years, with a specific focus on brain tumour research.

                    Glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required.

                    The overall research objective of GLIORESOLVE is to leverage a novel GBM tumour microenvironment (TME) classification system (developed during the recently completed Gliotrain Project), to establish new therapeutic strategies for GBM. Key outcomes expected from GLIORESOLVE are (1) to extend immunotherapy options to GBM patients and identify novel TME-subtype-specific therapeutic targets, (2) develop and optimise state-of-the-art pre-clinical models that recapitulate GBM TME-subtypes and (3) test novel rationally selected (available) drugs/drug combinations for precision treatment of GBM based on TME-subtype assignment.

                    The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology.

                    Thus, GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease. Moreover, the Doctoral Network addresses current needs in academia and the private sector to train PhD researchers in an environment that spans multiple disciplines. GLIORESOLVE candidates will be able to
                    navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

                    More information about the GlioResolve Doctoral Training unit can be found here: https://www.glioresolve.eu/recruitment

                    Project 5 :  PAtient-derived screening platform for probing personalised immunotherapies in TMe-based -gBM subtypes

                    Recruitment Location:  Luxembourg Institute of Health (LIH), Luxembourg
                    Main Supervisor: Dr Anna Golebiewska, Head of the NORLUX Neuro-Oncology Laboratory, LIH (anna.golebiewska@lih.lu)

                    Additional collaborators: Dr Else M Inderberg (Oslo University Hospital (OUS), Norway), Dr Daniel Stieber (Laboratoire national de santé (LNS), Dudelange, Luxembourg)

                    Project Summary: Differences in GBM TME composition are linked to several factors including patient-specific genetic, epigenetic aberrations and TME cues in spatially-distributed tumour niches. The research field is currently hampered by a lack of appropriate preclinical models allowing for assessment of the crosstalk between tumour and immune cells. Immunocompetent patient-derived organoids (PDOs) (i.e. co-cultures of tumour organoids with immune cells from patient or donor blood) and patient-derived orthotopic xenografts (PDOXs) developed in humanised mice (i.e. containing a partially reconstituted human immune system) are currently the most promising models for investigating immunotherapies in a patient-specific manner. To this end, the successful candidate will exploit the large LIH collection of PDOs and PDOXs as a platform to develop and probe a precision immunotherapeutic strategy based on TME-based GBM subtypes.
                    Expected secondments:
                    - 3 months (non-academic) to LNS, Dudelange, Luxembourg.
                    - 2 months (academic) to OUS, Oslo, Norway.

                    KeY SKILLS, EXPERIENCE AND QUALIFICATIONS
                    • Master in Biological Sciences, ideally with a focus on cancer biology or immunology.
                    • Strong background in cellular and molecular biology.
                    • Affinity to omics data and bioinformatics is a plus
                    • Motivated and eager to learn
                    • Excellent written, oral communication and organisational skills.
                    • Ability both to work independently and as part of a team.
                    • A previous related research experience is a distinct advantage


                    Candidate requirements
                    • Can be of any nationality, but are required to undertake transnational mobility as per the mobility rule.

                    • Should possess a Master’s degree in a relevant academic field (or equivalent)  

                    • Applications from candidates who already possess a doctoral degree will not be considered.

                    • Must be willing to travel (candidates must spend time on secondments in academic, clinical and/or private sector research institutions and must be willing to travel to organised training events over the course of the project).

                    • Must be able to start on the project by April 2023.


                    INFO

                    For informal inquiries regarding the application and eligibility questions, contact glioresolve@rcsi.ie.

                    For informal queries regarding specific projects, contact Dr Anna Golebiewska : anna.golebiewska@lih.lu

                    More information about the GlioResolve Doctoral Training unit can be found here: https://tinyurl.com/37nhvta7

                    More information about the Norlux Neuro-Oncology Laboratory can be found here: http://norlux.lu

                     

                     

                    IN SHORT...

                    • Contract type:       3- year fixed term contract (renewable for 1 year)
                    • Work hours:            Full time
                    • Location:                 Luxembourg
                    • Start date:              April  2023
                    • Salary:                     According to European Union's regulations: see explanation in the project description


                    HOW TO APPLY

                    Applicants should submit a full CV and motivation letter, which details the following:
                    - Up to three projects that they would like to apply for (see Project list : *).
                    - Description of previous research experiences.
                    - Contact details or recommendation letters of two referees.
                    - Proof of English language proficiency (where required.)


                    Only documents in English will be accepted, no later than 18:00 CET on December 23, 2022.
                    Email address to apply: glioresolve@rcsi.ie  - Only applications sent to this email address will be considered
                    Many thanks for writing in the subject line of the cover letter, the number of the selected projects (E.g. “Projects 1 and 3”)